These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25415928)

  • 21. Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231.
    Saito H; Tsunenari T; Onuma E; Sato K; Ogata E; Yamada-Okabe H
    Anticancer Res; 2005; 25(6B):3817-23. PubMed ID: 16309168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macrophage colony-stimulating factor release and receptor expression in bone cells.
    Weir EC; Horowitz MC; Baron R; Centrella M; Kacinski BM; Insogna KL
    J Bone Miner Res; 1993 Dec; 8(12):1507-18. PubMed ID: 8304053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
    Jun AY; Kim HJ; Park KK; Son KH; Lee DH; Woo MH; Chung WY
    Invest New Drugs; 2014 Feb; 32(1):1-13. PubMed ID: 23673814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases.
    van der Pluijm G; Sijmons B; Vloedgraven H; Deckers M; Papapoulos S; Löwik C
    J Bone Miner Res; 2001 Jun; 16(6):1077-91. PubMed ID: 11393785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteoprotegerin in bone metastases: mathematical solution to the puzzle.
    Ryser MD; Qu Y; Komarova SV
    PLoS Comput Biol; 2012; 8(10):e1002703. PubMed ID: 23093918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular mechanisms of bone resorption in breast carcinoma.
    Hunt NC; Fujikawa Y; Sabokbar A; Itonaga I; Harris A; Athanasou NA
    Br J Cancer; 2001 Jul; 85(1):78-84. PubMed ID: 11437406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
    Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
    Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin C-deficiency stimulates osteoclastogenesis with an increase in RANK expression.
    Hie M; Tsukamoto I
    J Nutr Biochem; 2011 Feb; 22(2):164-71. PubMed ID: 20444587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-3 inhibits human osteoclastogenesis and bone resorption through downregulation of c-Fms and diverts the cells to dendritic cell lineage.
    Gupta N; Barhanpurkar AP; Tomar GB; Srivastava RK; Kour S; Pote ST; Mishra GC; Wani MR
    J Immunol; 2010 Aug; 185(4):2261-72. PubMed ID: 20644169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
    Dougall WC; Chaisson M
    Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
    Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro.
    Al-Dujaili SA; Lau E; Al-Dujaili H; Tsang K; Guenther A; You L
    J Cell Biochem; 2011 Sep; 112(9):2412-23. PubMed ID: 21538477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity.
    Pederson L; Winding B; Foged NT; Spelsberg TC; Oursler MJ
    Cancer Res; 1999 Nov; 59(22):5849-55. PubMed ID: 10582709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.
    Liverani C; Mercatali L; Spadazzi C; La Manna F; De Vita A; Riva N; Calpona S; Ricci M; Bongiovanni A; Gunelli E; Zanoni M; Fabbri F; Zoli W; Amadori D; Ibrahim T
    Bone; 2014 Sep; 66():214-22. PubMed ID: 24956020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.